Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2014

View Archived Issues

Lundbeck characterizes novel brain-penetrant PDE2A inhibitor

Molecular Templates presents novel therapeutic candidate for multiple myeloma

Janssen presents novel FASN inhibitors for the treatment of cancer

AQP-5 expression and polymorphisms predict early breast cancer survival

Germline PIGA mutations linked to new genetic syndrome

Ace2 gene therapy reduces liver fibrosis in mice

Evotec presents novel FGFR-3 inhibitors

New series of ERK 2 inhibitors patented by Novartis

Sanofi patents new apelin receptor modulators

Pfizer discloses novel BACE inhibitors

Akebia Therapeutics completes enrollment in a phase IIb study of AKB-6548

IRM designs novel GPR119 receptor modulators

Mucosis enters into collaboration and license agreement with Changchun

Pivotal phase III study of veliparib begins in non-small cell lung cancer

Akron Biotech receives NIH grant for method to isolate stem cells

TT-genotype of IL-23R has protective effect in lung transplant recipients

Akros Pharma begins phase I study of JTT-251 in diabetes

Novel putative antisense mitochondrial RNA-based therapy for renal cell carcinoma

Cellmid signs MK Tribody agreement with Biotecnol

Dynavax initiates phase III trial to expand safety database for HBV vaccine

PanOptica completes financing round and starts dosing in phase I trial of anti-VEGF eye drop

FDA approves GSK's albiglutide BLA for type 2 diabetes

Kineta RLB joint venture formed to develop drugs for autoimmune disease

Wilson Therapeutics raises funding for development of Wilson's disease therapy

FDA approves trade name for Medac's subcutaneous methotrexate

BioAlliance and TopoTarget to merge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...